Nam H. Dang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nam H. Dang has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
C Morimoto
11Department of Lymphoma/Myeloma, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
4 shared publicationsU Aytac
11Department of Lymphoma/Myeloma, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
4 shared publications- Anas Younes
M. D. Anderson Cancer Center, Houston, TX
3 shared publications - Fernando Cabanillas
Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
3 shared publications K Ohnuma
22Department of Clinical Immunology and AIDS Research Center, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
3 shared publicationsPamela L. Walker
Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
3 shared publications
Latest Publications
- Open Access
Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma
BACKGROUND: T‐cell non‐Hodgkin lymphomas (T‐NHL) are more aggressive and patients have a poorer prognosis compared with patients with the corresponding B‐cell lymphomas. Although intensive treatments have been developed, it is unknown whether they are more effective than CHOP chemotherapy (cyclophosphamide, doxorubicin, oncovorin, and prednisone).METHODS: The authors' retrospective study evaluated the clinical outcome of 135 previously untreated patients with T‐NHL who were treated at The University of Texas M. D. Anderson Cancer Center (Houston, TX) between 1996 and 2002. Lymphomas with T‐cell histologies with the exception of mycosis fungoides were included.RESULTS: The estimated median overall survival was 46 months. Thirty‐seven percent of the patients received CHOP therapy, 48% received intensive therapy, and 15% received other therapy. The estimated 3‐year overall survival rates were 62% for the patients treated with CHOP therapy and 56% for the patients who received intensive therapy. After the exclusion of patients with anaplastic large cell lymphoma (ALCL), who are known to have a better prognosis than patients with other T‐NHLs, the estimated 3‐year overall survival rates were 43% for the patients treated with CHOP therapy and 49% for the patients who received intensive therapy. Parameters that may be independent prognostic factors for survival in T‐NHL, excluding ALCL, included ECOG performance status ≥ 2, beta‐2‐microglobulin level > 2 mg/L, lactate dehydrogenase level higher than normal, bulky disease ≥ 7 cm, and a higher international prognostic index and tumor score.CONCLUSIONS: The current study data suggested that patients treated with intensive therapies did not fare better than those treated with CHOP therapy. New treatment regimens need to be developed for patients with T‐NHL. Cancer 2005. © 2005 American Cancer Society.
Open AccessPrognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma
BACKGROUND: T‐cell non‐Hodgkin lymphomas (T‐NHL) are more aggressive and patients have a poorer prognosis compared with patients with the corresponding B‐cell lymphomas. Although intensive treatments have been developed, it is unknown whether they are more effective than CHOP chemotherapy (cyclophosphamide, doxorubicin, oncovorin, and prednisone).METHODS: The authors' retrospective study evaluated the clinical outcome of 135 previously untreated patients with T‐NHL who were treated at The University of Texas M. D. Anderson Cancer Center (Houston, TX) between 1996 and 2002. Lymphomas with T‐cell histologies with the exception of mycosis fungoides were included.RESULTS: The estimated median overall survival was 46 months. Thirty‐seven percent of the patients received CHOP therapy, 48% received intensive therapy, and 15% received other therapy. The estimated 3‐year overall survival rates were 62% for the patients treated with CHOP therapy and 56% for the patients who received intensive therapy. After the exclusion of patients with anaplastic large cell lymphoma (ALCL), who are known to have a better prognosis than patients with other T‐NHLs, the estimated 3‐year overall survival rates were 43% for the patients treated with CHOP therapy and 49% for the patients who received intensive therapy. Parameters that may be independent prognostic factors for survival in T‐NHL, excluding ALCL, included ECOG performance status ≥ 2, beta‐2‐microglobulin level > 2 mg/L, lactate dehydrogenase level higher than normal, bulky disease ≥ 7 cm, and a higher international prognostic index and tumor score.CONCLUSIONS: The current study data suggested that patients treated with intensive therapies did not fare better than those treated with CHOP therapy. New treatment regimens need to be developed for patients with T‐NHL. Cancer 2005. © 2005 American Cancer Society.
- Open Access
- 1 March 2005
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (5) , 1973-1983
Regulation of p38 Phosphorylation and Topoisomerase IIα Expression in the B-Cell Lymphoma Line Jiyoye by CD26/Dipeptidyl Peptidase IV Is Associated with EnhancedIn vitroandIn vivoSensitivity to Doxorubicin
CD26 is a Mr 110,000 surface-bound glycoprotein with diverse functional properties, including having a key role in normal T-cell physiology and the development of certain cancers. In this article, we show that surface expression of CD26, especially its intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity, results in enhanced topoisomerase IIα level in the B-cell line Jiyoye and subsequent in vitro sensitivity to doxorubicin-induced apoptosis. In addition, we show that expression of CD26/DPPIV is associated with increased phosphorylation of p38 and its upstream regulators mitogen-activated protein kinase kinase 3/6 and apoptosis signal-regulating kinase 1 and that p38 signaling pathway plays a role in the regulation of topoisomerase IIα expression. Besides demonstrating that CD26 effect on topoisomerase IIα and doxorubicin sensitivity is applicable to cell lines of both B-cell and T-cell lineages, the potential clinical implication of our work lies with the fact that we now show for the first time that our in vitro results can be extended to a severe combined immunodeficient mouse model. Our findings that CD26 expression can be an in vivo marker of tumor sensitivity to doxorubicin treatment may lead to future treatment strategies targeting CD26/DPPIV for selected human cancers in the clinical setting. Our article thus characterizes the biochemical linkage among CD26, p38, and topoisomerase IIα while providing evidence that CD26-associated topoisomerase IIα expression results in greater in vitro and in vivo tumor sensitivity to the antineoplastic agent doxorubicin.
- 1 March 2005
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (5) , 1973-1983
Open AccessRegulation of p38 Phosphorylation and Topoisomerase IIα Expression in the B-Cell Lymphoma Line Jiyoye by CD26/Dipeptidyl Peptidase IV Is Associated with EnhancedIn vitroandIn vivoSensitivity to Doxorubicin
CD26 is a Mr 110,000 surface-bound glycoprotein with diverse functional properties, including having a key role in normal T-cell physiology and the development of certain cancers. In this article, we show that surface expression of CD26, especially its intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity, results in enhanced topoisomerase IIα level in the B-cell line Jiyoye and subsequent in vitro sensitivity to doxorubicin-induced apoptosis. In addition, we show that expression of CD26/DPPIV is associated with increased phosphorylation of p38 and its upstream regulators mitogen-activated protein kinase kinase 3/6 and apoptosis signal-regulating kinase 1 and that p38 signaling pathway plays a role in the regulation of topoisomerase IIα expression. Besides demonstrating that CD26 effect on topoisomerase IIα and doxorubicin sensitivity is applicable to cell lines of both B-cell and T-cell lineages, the potential clinical implication of our work lies with the fact that we now show for the first time that our in vitro results can be extended to a severe combined immunodeficient mouse model. Our findings that CD26 expression can be an in vivo marker of tumor sensitivity to doxorubicin treatment may lead to future treatment strategies targeting CD26/DPPIV for selected human cancers in the clinical setting. Our article thus characterizes the biochemical linkage among CD26, p38, and topoisomerase IIα while providing evidence that CD26-associated topoisomerase IIα expression results in greater in vitro and in vivo tumor sensitivity to the antineoplastic agent doxorubicin.
- 15 October 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (20) , 4095-4102
Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Purpose: Denileukin diftitox is a fusion protein combining diphtheria toxin and interleukin-2 (IL-2) that targets tumor cells expressing the IL-2 receptor. Its efficacy has been shown in CD25+ cutaneous T-cell lymphoma, but not in B-cell non-Hodgkin's lymphoma (NHL). A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL. Patients and Methods: Patients with relapsed or refractory B-cell NHL were eligible. Tumor CD25 expression was determined by immunohistochemistry or flow cytometry. Denileukin diftitox was administered intravenously at a dose of 18 μg/kg once daily for 5 days every 3 weeks, up to eight cycles. Results: Of the 45 patients assessable for response, 32 (71%) were refractory to the last chemotherapy treatment, and all were previously treated with rituximab. Three complete responses (6.7%) and eight partial responses (17.8%) were observed, for an overall response rate of 24.5%. Nine patients (20%) had stable disease. Objective response rates were similar in CD25+ (22%) and CD25− histologies (29%), as were stable disease rates (22% and 18%, respectively). For responding patients, the median time to treatment failure was 7 months, with a median follow-up in survivors of 18 months (range, 9 to 28 months), and the projected progression-free survival at 20 months was 24% (95% CI, 0% to 60%). Most toxicities were low-grade and transient. Conclusion: Denileukin diftitox seems to be effective in relapsed or refractory, CD25+ and CD25− B-cell NHL and is well-tolerated at the dosage evaluated. Evaluation of denileukin diftitox in combination with other agents may be warranted.
- 15 October 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (20) , 4095-4102
Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Purpose: Denileukin diftitox is a fusion protein combining diphtheria toxin and interleukin-2 (IL-2) that targets tumor cells expressing the IL-2 receptor. Its efficacy has been shown in CD25+ cutaneous T-cell lymphoma, but not in B-cell non-Hodgkin's lymphoma (NHL). A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL. Patients and Methods: Patients with relapsed or refractory B-cell NHL were eligible. Tumor CD25 expression was determined by immunohistochemistry or flow cytometry. Denileukin diftitox was administered intravenously at a dose of 18 μg/kg once daily for 5 days every 3 weeks, up to eight cycles. Results: Of the 45 patients assessable for response, 32 (71%) were refractory to the last chemotherapy treatment, and all were previously treated with rituximab. Three complete responses (6.7%) and eight partial responses (17.8%) were observed, for an overall response rate of 24.5%. Nine patients (20%) had stable disease. Objective response rates were similar in CD25+ (22%) and CD25− histologies (29%), as were stable disease rates (22% and 18%, respectively). For responding patients, the median time to treatment failure was 7 months, with a median follow-up in survivors of 18 months (range, 9 to 28 months), and the projected progression-free survival at 20 months was 24% (95% CI, 0% to 60%). Most toxicities were low-grade and transient. Conclusion: Denileukin diftitox seems to be effective in relapsed or refractory, CD25+ and CD25− B-cell NHL and is well-tolerated at the dosage evaluated. Evaluation of denileukin diftitox in combination with other agents may be warranted.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 8080
Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study
8080 Background: Individuals older than 60 years have a worse prognosis than younger patients with aggressive NHL. Vincristine is active in malignant lymphomas. Sphingosomal vincristine (SV) was well tolerated with 45% ORR in multiply relapsed aggressive NHL (ASH Abst. 412, 1999). Based on these data, a phase II study of CHOP with or without rituximab, and substituting SV for free vincristine, was undertaken in patients with previously untreated aggressive NHL. Methods: Patients were treated with standard dose CHOP that included SV 2.0 mg/m2 without dose capping ± rituximab 375 mg/m2, given every 21 days for 6 to 8 courses (ASH abst. 338, 2002). Results: Of 73 patients enrolled on study, 68 were evaluable for response. Median age was 63 (range 22–80), 37 pts (54%) were > 60. Overall, 24 pts (23 elderly) had an IPI score ≥ 3. Patients received a median of 6 study treatments (range 1–8). ORR was 92.6% (63/68 pts) with 55 pts achieving CR (80.1%), 7 CRu (10.3%), and 1 PR (1.5%). 3 pts had PD (4.4%) and 2 were not assessed for response (2.9%). ORR was similar in both elderly (>60) and younger pts (≤ 60): 91.9% and 93.5% respectively. The median PFS and OS have not been reached at a median follow up of 22 months. The probability of being progression free at 17 mos was 0.88 (5 relapses) for elderly pts and 0.86 (4 relapses) for pts ≤ 60. Overall survival probability was 0.98 (1 death) at 22 mos. Neuropathy was generally mild (Gr.1-2). Hematological toxicities were as follows: 56% Gr.3-4 neutropenia, 6% Gr.3 anemia, and 13% Gr.3-4 thrombocytopenia. Toxicites were comparable in both elderly and younger patients. Conclusions: CHOP plus rituximab regimen with sphingosomal vincristine substituted for free vincristine is a well tolerated therapy with only mild neurotoxicity. Remarkably, the activity in the elderly is comparable to that in younger patients.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 8080
Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study
8080 Background: Individuals older than 60 years have a worse prognosis than younger patients with aggressive NHL. Vincristine is active in malignant lymphomas. Sphingosomal vincristine (SV) was well tolerated with 45% ORR in multiply relapsed aggressive NHL (ASH Abst. 412, 1999). Based on these data, a phase II study of CHOP with or without rituximab, and substituting SV for free vincristine, was undertaken in patients with previously untreated aggressive NHL. Methods: Patients were treated with standard dose CHOP that included SV 2.0 mg/m2 without dose capping ± rituximab 375 mg/m2, given every 21 days for 6 to 8 courses (ASH abst. 338, 2002). Results: Of 73 patients enrolled on study, 68 were evaluable for response. Median age was 63 (range 22–80), 37 pts (54%) were > 60. Overall, 24 pts (23 elderly) had an IPI score ≥ 3. Patients received a median of 6 study treatments (range 1–8). ORR was 92.6% (63/68 pts) with 55 pts achieving CR (80.1%), 7 CRu (10.3%), and 1 PR (1.5%). 3 pts had PD (4.4%) and 2 were not assessed for response (2.9%). ORR was similar in both elderly (>60) and younger pts (≤ 60): 91.9% and 93.5% respectively. The median PFS and OS have not been reached at a median follow up of 22 months. The probability of being progression free at 17 mos was 0.88 (5 relapses) for elderly pts and 0.86 (4 relapses) for pts ≤ 60. Overall survival probability was 0.98 (1 death) at 22 mos. Neuropathy was generally mild (Gr.1-2). Hematological toxicities were as follows: 56% Gr.3-4 neutropenia, 6% Gr.3 anemia, and 13% Gr.3-4 thrombocytopenia. Toxicites were comparable in both elderly and younger patients. Conclusions: CHOP plus rituximab regimen with sphingosomal vincristine substituted for free vincristine is a well tolerated therapy with only mild neurotoxicity. Remarkably, the activity in the elderly is comparable to that in younger patients.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 8066
A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma
8066 Background: Melatonin is a hormone made in the pineal gland that regulates sleep and influences other hormonal body functions. Studies by Lissoni, et al. (Supportive Care in Cancer. 5: 126,1997) also suggest a myeloprotective effect when administered with chemotherapy. To assess the myeloprotective effect of melatonin on patients receiving CHOP chemotherapy, we conducted the following trial. Methods: Eligible patients had newly diagnosed, histologically proven, large B-cell lymphoma with a favorable prognosis (M.D. Anderson Tumor Score<3. Rodriguez, et al. Ann Oncol. 3: 711–717, 1992). Patients were treated with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) every three weeks and were randomized to take or not to take melatonin 20 mg daily by mouth for 18 weeks starting on day 1 of course1. Weekly CBC's with differentials were obtained after cycle 1. The primary endpoint was the incidence of neutropenia (neutrophil count ≤ 500) after the first course of chemotherapy. Results: Between 1998 and 2001, 112 evaluable patients were enrolled on the study. 56 were randomized to each arm. Baseline characteristics were statistically similar between the groups. The median age was 54 and the International Prognostic Index score was ≤3 in 96% of patients. 51 patients experienced a neutrophil nadir ≤ 500 after course 1 of chemotherapy; 26 were in the arm with melatonin, 25 were in the arm without melatonin (p=0.78). Tests of association between the treatment group and secondary measured parameters including the nadir ANC, change in hemoglobin, change in platelet count, CR rate, and infection rate were not statistically significant. Overall survival was estimated to be 95% at three years in both arms. The three year failure-free survival was 75% in both treatment groups. Conclusions: The addition of melatonin to CHOP chemotherapy did not decrease the incidence of neutropenia after cycle 1 in this patient population. In addition, this study suggests that there is no improvement in neutrophil nadir, CR rate, infection rate, or change in hemoglobin or platelet counts with the addition of melatonin. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 8066
A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma
8066 Background: Melatonin is a hormone made in the pineal gland that regulates sleep and influences other hormonal body functions. Studies by Lissoni, et al. (Supportive Care in Cancer. 5: 126,1997) also suggest a myeloprotective effect when administered with chemotherapy. To assess the myeloprotective effect of melatonin on patients receiving CHOP chemotherapy, we conducted the following trial. Methods: Eligible patients had newly diagnosed, histologically proven, large B-cell lymphoma with a favorable prognosis (M.D. Anderson Tumor Score<3. Rodriguez, et al. Ann Oncol. 3: 711–717, 1992). Patients were treated with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) every three weeks and were randomized to take or not to take melatonin 20 mg daily by mouth for 18 weeks starting on day 1 of course1. Weekly CBC's with differentials were obtained after cycle 1. The primary endpoint was the incidence of neutropenia (neutrophil count ≤ 500) after the first course of chemotherapy. Results: Between 1998 and 2001, 112 evaluable patients were enrolled on the study. 56 were randomized to each arm. Baseline characteristics were statistically similar between the groups. The median age was 54 and the International Prognostic Index score was ≤3 in 96% of patients. 51 patients experienced a neutrophil nadir ≤ 500 after course 1 of chemotherapy; 26 were in the arm with melatonin, 25 were in the arm without melatonin (p=0.78). Tests of association between the treatment group and secondary measured parameters including the nadir ANC, change in hemoglobin, change in platelet count, CR rate, and infection rate were not statistically significant. Overall survival was estimated to be 95% at three years in both arms. The three year failure-free survival was 75% in both treatment groups. Conclusions: The addition of melatonin to CHOP chemotherapy did not decrease the incidence of neutropenia after cycle 1 in this patient population. In addition, this study suggests that there is no improvement in neutrophil nadir, CR rate, infection rate, or change in hemoglobin or platelet counts with the addition of melatonin. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 6603
Prognostic factors in patients with T-cell non-Hodgkin's lymphoma
6603 Background: T-cell non-Hodgkin's lymphomas (T-NHL) are generally more aggressive and have a poorer prognosis compared to the corresponding B-cell lymphoma. Methods: This retrospective study examines the clinical outcome of 135 previously untreated patients with T-NHL seen at M.D. Anderson Cancer Center between 1996 and 2002. All T-cell histologies with the exception of mycosis fungoides were included. Results: With a minimum follow-up of 13 months, the estimated median overall survival was 46 months. Patients with age > 60, disease stage ≥3, extensive extranodal involvement, performance status ≥3, hemoglobin < 10, beta 2- microglobulin > 3, LDH > normal, and T-cell histologies other than CD30+ T-anaplastic large cell lymphoma (T-ALCL) had significantly worse 3-year overall survival. We then evaluated the overall survival based on the following 3 treatment groups: (1) CHOP therapy, (2) intensive therapy, which includes patients treated with hyperCHOP, hyperCVAD, ATT, and autologous stem cell transplant, (3) “other” therapy, which includes patients treated with any other alternative regimen. Thirty-seven percent of patients received CHOP therapy, 48% received intensive therapy, and 15% received “other” therapy. The 3-year overall survival was 62% in the patients treated with CHOP therapy and 56% in the patients treated with intensive therapy. After exclusion of CD30+ T-ALCL, which is known to have a better prognosis than the other T-cell histologies, the 3-year overall survival was 43% in the patients treated with CHOP therapy and 49% in the patients treated with the intensive therapy. Conclusions: (1) Parameters that may be independent prognostic factors for survival in T-NHL include: age, stage, extranodal involvement, performance status, hemoglobin, beta 2-microglobulin, LDH, and T-cell histology. (2) Consistent with previous findings, CD30+ T-ALCL has a better prognosis than other T cell histologies when treated with standard CHOP therapy. (3) Our data suggests that patients treated with the prior intensive therapies at our institution did not fare better than standard CHOP therapy. New treatment regimens need to be considered for T-NHL. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 6603
Prognostic factors in patients with T-cell non-Hodgkin's lymphoma
6603 Background: T-cell non-Hodgkin's lymphomas (T-NHL) are generally more aggressive and have a poorer prognosis compared to the corresponding B-cell lymphoma. Methods: This retrospective study examines the clinical outcome of 135 previously untreated patients with T-NHL seen at M.D. Anderson Cancer Center between 1996 and 2002. All T-cell histologies with the exception of mycosis fungoides were included. Results: With a minimum follow-up of 13 months, the estimated median overall survival was 46 months. Patients with age > 60, disease stage ≥3, extensive extranodal involvement, performance status ≥3, hemoglobin < 10, beta 2- microglobulin > 3, LDH > normal, and T-cell histologies other than CD30+ T-anaplastic large cell lymphoma (T-ALCL) had significantly worse 3-year overall survival. We then evaluated the overall survival based on the following 3 treatment groups: (1) CHOP therapy, (2) intensive therapy, which includes patients treated with hyperCHOP, hyperCVAD, ATT, and autologous stem cell transplant, (3) “other” therapy, which includes patients treated with any other alternative regimen. Thirty-seven percent of patients received CHOP therapy, 48% received intensive therapy, and 15% received “other” therapy. The 3-year overall survival was 62% in the patients treated with CHOP therapy and 56% in the patients treated with intensive therapy. After exclusion of CD30+ T-ALCL, which is known to have a better prognosis than the other T-cell histologies, the 3-year overall survival was 43% in the patients treated with CHOP therapy and 49% in the patients treated with the intensive therapy. Conclusions: (1) Parameters that may be independent prognostic factors for survival in T-NHL include: age, stage, extranodal involvement, performance status, hemoglobin, beta 2-microglobulin, LDH, and T-cell histology. (2) Consistent with previous findings, CD30+ T-ALCL has a better prognosis than other T cell histologies when treated with standard CHOP therapy. (3) Our data suggests that patients treated with the prior intensive therapies at our institution did not fare better than standard CHOP therapy. New treatment regimens need to be considered for T-NHL. No significant financial relationships to disclose.
- Open Access
- 30 September 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (7) , 1366-1374
CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
CD26/dipeptidyl peptidase IV (DPPIV) is a cell surface-bound ectopeptidase with important roles in T-cell activation and tumour biology. We now report that CD26/DPPIV enhances sensitivity to apoptosis induced by the antineoplastic agents doxorubicin and etoposide. In particular, CD26/DPPIV presence is associated with increased susceptibility to the mitochondrial pathway of apoptosis, documented by enhanced cleavage of poly (ADP ribose) polymerase (PARP), caspase-3 and caspase-9, Bcl-xl, and Apaf-1, as well as increased expression of death receptor 5 (DR5). We also show that the caspase-9-specific inhibitor z-LEHD-fmk inhibits drug-mediated apoptosis, leading to decreased PARP and caspase-3 cleavage, and reduced DR5 expression. Importantly, through detailed studies that demonstrate the association between topoisomerase II alpha expression and DPPIV activity, our data provide further evidence of the key role played by CD26 in biological processes.
- 30 September 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (7) , 1366-1374
Open AccessCD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
CD26/dipeptidyl peptidase IV (DPPIV) is a cell surface-bound ectopeptidase with important roles in T-cell activation and tumour biology. We now report that CD26/DPPIV enhances sensitivity to apoptosis induced by the antineoplastic agents doxorubicin and etoposide. In particular, CD26/DPPIV presence is associated with increased susceptibility to the mitochondrial pathway of apoptosis, documented by enhanced cleavage of poly (ADP ribose) polymerase (PARP), caspase-3 and caspase-9, Bcl-xl, and Apaf-1, as well as increased expression of death receptor 5 (DR5). We also show that the caspase-9-specific inhibitor z-LEHD-fmk inhibits drug-mediated apoptosis, leading to decreased PARP and caspase-3 cleavage, and reduced DR5 expression. Importantly, through detailed studies that demonstrate the association between topoisomerase II alpha expression and DPPIV activity, our data provide further evidence of the key role played by CD26 in biological processes.
- 1 September 2003
- Published by Spandidos Publications in Oncology Reports
- Vol. 10 (5) , 1513-1518
Pentostatin in T-non-Hodgkin's lymphomas: Efficacy and effect on CD26+ T lymphocytes
Pentostatin is an adenosine deaminase (ADA) inhibitor with antineoplastic activity. CD26 is a surface glycoprotein with a key role in T cell function as the ADA binding protein. We conducted a phase II study to evaluate pentostatin efficacy in relapsed T-non-Hodgkin's lymphoma (T-NHL) and to correlate response with tumor CD26 expression. We also examined the lymphopenic effect of pentostatin on CD26+ T lymphocytes. Eighteen patients were registered for the study. Pentostatin was administered as intravenous bolus daily over 3 days at an initial dose of 5 mg/m(2)/day, repeated every 4 weeks. CD26 surface expression on tumor cells and T lymphocytes was determined by flow cytometry. Out of 14 patients evaluable for response, there was 1 (7%) complete response (CR) and 6 (43%) partial responses (PR). Median progression-free survival for responders was 6 months (range: 2-15 months); median number of courses was 4 (range: 1-6). Responders included 1 of 2 CD26+ and 5 of 9 CD26- cases. Pentostatin also specifically depleted CD26+ rather than CD26- T lymphocytes, potentially associated with immunosuppression. We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications.
- 1 September 2003
- Published by Spandidos Publications in Oncology Reports
- Vol. 10 (5) , 1513-1518
Pentostatin in T-non-Hodgkin's lymphomas: Efficacy and effect on CD26+ T lymphocytes
Pentostatin is an adenosine deaminase (ADA) inhibitor with antineoplastic activity. CD26 is a surface glycoprotein with a key role in T cell function as the ADA binding protein. We conducted a phase II study to evaluate pentostatin efficacy in relapsed T-non-Hodgkin's lymphoma (T-NHL) and to correlate response with tumor CD26 expression. We also examined the lymphopenic effect of pentostatin on CD26+ T lymphocytes. Eighteen patients were registered for the study. Pentostatin was administered as intravenous bolus daily over 3 days at an initial dose of 5 mg/m(2)/day, repeated every 4 weeks. CD26 surface expression on tumor cells and T lymphocytes was determined by flow cytometry. Out of 14 patients evaluable for response, there was 1 (7%) complete response (CR) and 6 (43%) partial responses (PR). Median progression-free survival for responders was 6 months (range: 2-15 months); median number of courses was 4 (range: 1-6). Responders included 1 of 2 CD26+ and 5 of 9 CD26- cases. Pentostatin also specifically depleted CD26+ rather than CD26- T lymphocytes, potentially associated with immunosuppression. We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications.
- Open Access
- 10 February 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (3) , 455-462
Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors
CD26/dipeptidyl peptidase IV (DPPIV) is a surface antigen with multiple functions, including a role in T-cell activation and the development of certain human cancers. We previously demonstrated that CD26/DPPIV enhanced sensitivity of Jurkat cells to doxorubicin. We now show that expression of CD26/DPPIV enhanced sensitivity of CD26 Jurkat transfectants to G2–M arrest mediated by the antineoplastic agent etoposide. The increased sensitivity to etoposide-induced G2–M arrest was associated with disruption of cell cycle-related events, including hyperphosphorylation of p34cdc2 kinase, change in cdc25C expression and phosphorylation, and alteration in cyclin B1 expression. CD26/DPPIV-associated enhancement of doxorubicin and etoposide-induced G2–M arrest was also observed in serum-free media, suggesting an effect of CD26 on cell-derived processes rather than serum-derived factors. Importantly, our work elucidated a potential mechanism for the enhanced susceptibility of CD26-expressing Jurkat cells to the topoisomerase II inhibitors by demonstrating that CD26/DPPIV surface expression was associated with increased topoisomerase II α levels and enhanced enzyme activity. Besides being the first to show a functional association between the multifaceted molecule CD26 and the key cellular protein topoisomerase II α, our studies provide additional evidence of a potential role for CD26 in the treatment of selected malignancies.
- 10 February 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (3) , 455-462
Open AccessEffect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors
CD26/dipeptidyl peptidase IV (DPPIV) is a surface antigen with multiple functions, including a role in T-cell activation and the development of certain human cancers. We previously demonstrated that CD26/DPPIV enhanced sensitivity of Jurkat cells to doxorubicin. We now show that expression of CD26/DPPIV enhanced sensitivity of CD26 Jurkat transfectants to G2–M arrest mediated by the antineoplastic agent etoposide. The increased sensitivity to etoposide-induced G2–M arrest was associated with disruption of cell cycle-related events, including hyperphosphorylation of p34cdc2 kinase, change in cdc25C expression and phosphorylation, and alteration in cyclin B1 expression. CD26/DPPIV-associated enhancement of doxorubicin and etoposide-induced G2–M arrest was also observed in serum-free media, suggesting an effect of CD26 on cell-derived processes rather than serum-derived factors. Importantly, our work elucidated a potential mechanism for the enhanced susceptibility of CD26-expressing Jurkat cells to the topoisomerase II inhibitors by demonstrating that CD26/DPPIV surface expression was associated with increased topoisomerase II α levels and enhanced enzyme activity. Besides being the first to show a functional association between the multifaceted molecule CD26 and the key cellular protein topoisomerase II α, our studies provide additional evidence of a potential role for CD26 in the treatment of selected malignancies.
- 1 October 2002
- Vol. 17 (4) , 1213-26
CD26: an expanding role in immune regulation and cancer.
In this review, we highlight major aspects of the biology of CD26, a dipeptidyl peptidase IV (DPPIV)-containing surface glycoprotein with multiple functions. In particular, we discuss findings demonstrating that CD26/DPPIV has an essential role in immune regulation as a T cell activation molecule and a regulator of chemokine function. We also review recent studies that identify key cellular molecules that physically associate with CD26 and the potential consequences of their interaction, including those with clinically-related implications. Furthermore, we present work suggesting a role for CD26 in the pathogenesis and behavior of selected human cancers, both solid tumors and hematological malignancies. We present recent studies that investigate the potential role of CD26 as a molecular target for novel treatment modalities for T cell lymphoid malignancies and possibly other hematological malignancies, with work involving the use of anti-CD26 monoclonal antibody, CD26-transfected cells as well as soluble CD26 molecules.
- 1 October 2002
- Vol. 17 (4) , 1213-26
CD26: an expanding role in immune regulation and cancer.
In this review, we highlight major aspects of the biology of CD26, a dipeptidyl peptidase IV (DPPIV)-containing surface glycoprotein with multiple functions. In particular, we discuss findings demonstrating that CD26/DPPIV has an essential role in immune regulation as a T cell activation molecule and a regulator of chemokine function. We also review recent studies that identify key cellular molecules that physically associate with CD26 and the potential consequences of their interaction, including those with clinically-related implications. Furthermore, we present work suggesting a role for CD26 in the pathogenesis and behavior of selected human cancers, both solid tumors and hematological malignancies. We present recent studies that investigate the potential role of CD26 as a molecular target for novel treatment modalities for T cell lymphoid malignancies and possibly other hematological malignancies, with work involving the use of anti-CD26 monoclonal antibody, CD26-transfected cells as well as soluble CD26 molecules.